These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9873106)

  • 1. Toxicity antagonists in head and neck cancer.
    Trotti A
    Semin Radiat Oncol; 1998 Oct; 8(4):282-91. PubMed ID: 9873106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered fractionation: limited by mucosal reactions?
    Kaanders JH; van der Kogel AJ; Ang KK
    Radiother Oncol; 1999 Mar; 50(3):247-60. PubMed ID: 10392810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head and neck squamous cell carcinoma: optimizing the therapeutic index.
    Rosenthal DI; Blanco AI
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):501-14. PubMed ID: 16001957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
    Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
    Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical component of supportive care.
    Murphy BA
    J Support Oncol; 2007 May; 5(5):228-9. PubMed ID: 17564152
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicity in head and neck cancer: a review of trends and issues.
    Trotti A
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):1-12. PubMed ID: 10758302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
    Bartelink H; Van den Bogaert W; Horiot JC; Jager J; van Glabbeke M
    Eur J Cancer; 2002 Mar; 38(5):667-73. PubMed ID: 11916549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of saliva in oral health: strategies for prevention and management of xerostomia.
    Brosky ME
    J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.
    O'Neill CB; Baxi SS; Atoria CL; O'Neill JP; Henman MC; Sherman EJ; Lee NY; Pfister DG; Elkin EB
    Cancer; 2015 Jun; 121(12):2083-9. PubMed ID: 25728057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients.
    Willey CD; Murphy BA; Netterville JL; Burkey BB; Shyr Y; Shakhtour B; Kish B; Raben D; Chen C; Song JI; Kane MA; Cmelak AJ
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1323-31. PubMed ID: 17289289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers.
    Spiotto MT; Connell PP
    Oral Maxillofac Surg Clin North Am; 2016 Feb; 28(1):115-26. PubMed ID: 26614704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Adelstein D; Vermorken JB
    Oral Oncol; 2018 Jan; 76():52-60. PubMed ID: 29290286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of sucralfate in radiation oncology].
    Belka C; Hoffmann W; Paulsen F; Barnberg M
    Strahlenther Onkol; 1997 May; 173(5):247-52. PubMed ID: 9198905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal protectants and their application for head and neck chemoirradiation.
    Marks JE
    Curr Opin Oncol; 1997 May; 9(3):267-73. PubMed ID: 9229150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of early and late toxicities in chemoradiation trials.
    Bentzen SM; Trotti A
    J Clin Oncol; 2007 Sep; 25(26):4096-103. PubMed ID: 17827459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of Cepharanthin to prevent radiation induced xerostomia in head and neck cancer].
    Imada H; Nomoto S; Ohguri T; Yahara K; Kato F; Morioka T; Korogi Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1041-5. PubMed ID: 15272582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.